Your browser does not support JavaScript or it may be disabled!
rediff.com
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
NEWS ON MOBILE
Get Realtime News
on your webpage

About 124 results for "Mk 5172"

The Combination of Grazoprevir (MK-5172), an NS3 Inhibitor, an...

65th Annual Meeting of the American Association for the Study of Liver Diseases Boston, MA Nov 7-11 2014 Reported by Jules Levin AASLD 2014 Nov 7-11 Boston Fred Lahser1, Karin Bystol1, Stephanie Curry1, Patricia McMonagle1, Rong Liu1, Ellen ... National AIDS Treatment Advocacy Project, 1 month ago

5 images for Mk 5172

MDLinx, 1 month ago
MDLinx, 1 month ago
Citybizlist, 2 months ago
Securities Technology Monitor, 2 months ago
Jutia Group, 2 months ago

Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous

The Lancet, Early Online Publication, 11 November 2014 Eric Lawitz, Edward Gane, Brian Pearlman, Edward Tam, Wayne Ghesquiere, Dominique Guyader, Laurent Alric, Jean-Pierre Bronowicki, Laura Lester, William Sievert, Reem Ghalib, Luis Balart, ...
 National AIDS Treatment Advocacy Project1 month ago Excellent Results for 12 and 18 Weeks of Merck's Dual Hep C Regimen  AIDSmeds1 month ago Merck (MRK) Updates on MK-5172/MK-8742 Phase 2  Wall Street Business Network1 month ago Efficacy and safety of MK-5172 and MK-8742 ± RIBAVIRIN IN Hcv Gt1 Infected Patients with cirrhosis or previous null reSPonse: FINAL RESULTS OF the C-WORTHY Study (PARTS A AND B)  National AIDS Treatment Advocacy Project1 month ago
[x]  
Bioresearch Online

Merck to Present New Data from Clinical Studies Evaluating Investigational Hepatitis C Treatment Grazoprevir/Elbasvir MK-5172/MK-8742 at the 65th...

Merck to Present New Data from Clinical Studies Evaluating Investigational Hepatitis C Treatment Grazoprevir/Elbasvir MK-5172/MK-8742 at the 65th American Association for the Study of Liver Diseases Annual Meeting By a News Reporter-Staff News ...
 4 Traders2 months ago Merck Posts Data For Triple-Drug HCV Regimen  Bioresearch Online1 month ago MERCK : Announces Results from Phase 2 Study of Investigational Chronic Hepatitis C Treatment Grazoprevir/Elbasvir in Genotype 1 Infected Treatment-Nave and Difficult-to-Cure Patients  4 Traders1 month ago Merck & Co.???s Investigational Hepatitis C Treatment Grazoprevir/Elbasvir In Combination With A Nucleotide Inhibitor (C-SWIFT Study) Presented At The Liver Meeting??  BioSpace1 month ago
[x]  
Motley Fool

The Hepatitis C Drug Developer That Crushed Gilead Sciences, Inc. in 2014 (Hint: It's Not AbbVie)

For shareholders of Gilead Sciences (NASDAQ: GILD Gilead's giant leap forward Sovaldi and Harvoni both represent major breakthroughs in HCV patient quality of care in that neither Sovaldi (geared toward genotype 2 and 3 HCV) nor Harvoni (targeted ...
 Motley Fool1 day ago Sovaldi Can't Sustain The Current Prices Of Gilead Sciences' Stock: Algorithmic And Fundamental Analysis  Seeking Alpha1 week ago Is AbbVie's Bullishness On Its Hepatitis C Drugs Valid?  Seeking Alpha1 month ago
Nasdaq

Could Gilead Sciences, Inc. Be a Top Stock in 2015?

GILD data by YCharts Despite last weeks' oil-induced swoon, the S&P 500 is still up by 8% for the year. But don't bother bragging about this to Gilead Sciences shareholders -- through the weekend, Gilead shares had nearly quintupled the broader ...
 Nasdaq3 days ago

A Future Without Hepatitis C?

Bourlière M, Sulkowski MS, Omata M, et al. An integrated safety and efficacy analysis of >500 patients with compensated cirrhosis treated with ledipasvir/sofosbuvir with or without RBV. Program and abstracts of the 65th annual meeting of the ...
 General Medicine eJournal1 week ago

Summary from AASLD 2014 for Hepatitis C Boston 7-11 November 2014

65th Annual Meeting of the American Association for the Study of Liver Diseases Boston, MA Nov 7-11 2014 Feedback from the real-world: do HCV cure rates in real-life patient cohorts hold what clinical trials promised? Summary from AASLD 2014 ...
 National AIDS Treatment Advocacy Project2 weeks ago
Citybizlist

5 Things Merck & Co., Inc.'s Management Wants You to Know

Source: Merck & Co. It's been about a month since pharmaceutical giant Merck (NYSE: MRK ) reported its third-quarter results, but time hasn't changed the fact that Merck's been struggling mightily with patent expirations and increased competition ...
 Citybizlist3 weeks ago Do Merck's Recent Hepatits C Trial Results Weaken Its Position?  Trefis1 month ago Merck's triple-therapy hepatitis C regimen shows sub-optimal efficacy  Pharma Letter1 month ago Merck Reports Interim Data on Hepatitis C Virus Drug  Yahoo! Finance1 month ago
[x]  

Drug Delivery: Lessons to Be Learnt From Leishmania Studies

Heyneman D. Immunology of leishmaniasis. Bull. World Health Organ. 44(4), 499514 (1971). Antoine JC, Prina E, Lang T et al. The biogenesis and properties of the parasitophorous vacuoles that harbour Leishmania in murine macrophages. Trends ...
 Medscape1 month ago

Investigational HCV Combo Delivers in Differing Groups

Gastroenterology Published: Nov 16, 2014 BOSTON -- A new study suggests that some subgroups of patients with hepatitis C (HCV) infection can achieve sustained virologic responses (SVR) in as short as 4 weeks using an aggressive, investigational ...
 MedPage Today1 month ago Shorter Treatment Shows Promise With Investigative HCV Agents  MedPage Today1 month ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
1.
2.
3.
4.
5.
6.
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts

Get

Realtime News

on your Webpage

Add Widget >Get your members hooked!
    
Alerts
Get updated on latest news & your favorite topics right in your inbox!
 
More     Less